



(11) **EP 2 275 087 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 9/16** (2006.01) **A61K 9/20** (2006.01)  
**A61K 31/4365** (2006.01)

(48) Corrigendum issued on:  
**21.11.2012 Bulletin 2012/47**

(45) Date of publication and mention  
of the grant of the patent:  
**05.09.2012 Bulletin 2012/36**

(21) Application number: **10154259.5**

(22) Date of filing: **22.02.2010**

(54) **Prasugrel controlled release formulations**

Formulierungen mit gesteuerter Freisetzung von Prasugrel

Formulations de libération contrôlée de prasugrel

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL**  
**PT RO SE SI SK SM TR**

(43) Date of publication of application:  
**19.01.2011 Bulletin 2011/03**

(73) Proprietor: **JRS Pharma GmbH & Co. KG**  
**73494 Rosenberg (DE)**

(72) Inventor: **Dr. Glänzer, Klaus**  
**22337, Hamburg (DE)**

(74) Representative: **Becker Kurig Straus**  
**Bavariastrasse 7**  
**80336 München (DE)**

(56) References cited:  
**EP-A1- 2 360 159 WO-A2-2004/098713**  
**US-A1- 2007 243 243 US-A1- 2009 281 136**

**EP 2 275 087 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).